Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Plant-Based diet shows promise for diabetes remission in new study

NCT ID NCT05372445

Disease control Sponsor: National Council of Scientific and Technical Research, Argentina Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a plant-based diet and lifestyle changes could help people with type 2 diabetes, prediabetes, or obesity improve their health. Researchers aimed for diabetes remission (normal blood sugar without medication for at least 3 months) or significant weight loss. The study enrolled 468 participants and tracked their gut bacteria and health over 2 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

468 people

The number who actually took part.

Started

May 2022

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for control or reference group: * Subjects without type 2 diabetes, obesity, prediabetes (glucose intolerance), or metabolic syndrome * HbA1c less than 42mmol/mol (\<5.7%) * BMI between 18.5 and 24.9 Inclusion Criteria for people with obesity: * BMI greater than 30 Inclusion Criteria for people with prediabetes: * Fasting glucose between 110 and 125 mg/dl * HbA1c between 42 and 47 mmol/mol (5.7% to 6.4%) * BMI greater than 30 Inclusion Criteria for people with type 2 diabetes: * Fasting glucose \> 126 mg/dl * HbA1c \> 48mmol/mol (6.5% or higher) * BMI greater than 30 * Treatment with metformin at therapeutic dose (1500-2000 mg/day) or maximum tolerated dose. Exclusion Criteria: * Subjects with obesity, pre-diabetes medicated with metformin or another drug for diabetes or obesity * Subjects with type 2 diabetes medicated with another drug that is not metformin * Subjects with type 2 diabetes diagnosed over 6 years * Subjects with type 2 diabetes requiring insulin * Chronic kidney disease grade greater than 3 (measured by EPI) * Subjects with type 1 diabetes * Intestinal diseases, Crohn's, ulcerative colitis, celiac disease * Use of antibiotics in the last 3 months * Pregnancy, lactation * Psychiatric disorders * Eating disorder * Gastric bypass surgery * Transplanted people * Oncological pathology diagnosed less than 5 years * Subjects who do not wish to sign the informed consent * Subjects who do not agree to participate in the study over the 2 years follow-up * Subjects who do not have electronic devices and the internet to hold virtual meetings

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic syndrome X Obesity obesity disorder prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Obesity Prediabetes

Contacts and locations

Locations

  • Hospital de Clínicas "José de San Martín"

    Capital Federal, Buenos Aires, C1120AAR, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.